When you compare MT-1 and MT-2, receptor selectivity drives everything. MT-1’s a linear tridecapeptide that locks onto MC1R, preserving the α-MSH pharmacophore for melanocyte-focused signaling and melanogenesis. MT-2’s a cyclic heptapeptide whose constrained lactam geometry produces pan-agonist activity across MC1R, MC3R, MC4R, and MC5R. That single structural difference determines your readout: MT-1 gives you mechanistic precision, while MT-2 yields mixed phenotypes. The sections below cover how to choose.
Key Takeaways
- MT-1 (afamelanotide) is a linear tridecapeptide with MC1R-dominant activity, preserving the native α-MSH pharmacophore.
- MT-2 (Melanotan II) is a cyclic heptapeptide whose constrained lactam geometry drives a broad pan-melanocortin agonist profile.
- MT-1 shows dominant MC1R activity but minimal engagement at MC3R, MC4R, and MC5R.
- MT-2 is active across MC1R, MC3R, MC4R, and MC5R, with little meaningful affinity at MC2R.
- MT-1 enables MC1R-specific mechanistic precision, while MT-2’s mixed signaling complicates receptor attribution in studies.
How do MT-1 and MT-2 differ in receptor selectivity
MT-1 is MC1R-dominant, whereas MT-2 is broadly active across multiple melanocortin receptors. MT-1, a linear tridecapeptide, preserves the α-MSH pharmacophore, driving MC1R-dominant activity. MT-2, a cyclic heptapeptide, engages multiple melanocortin receptors, producing a pan-agonist profile. That structural contrast dictates everything about how each behaves in your experimental models.
| Receptor | MT-1 | MT-2 |
|---|---|---|
| MC1R | Dominant | Active |
| MC3R | Minimal | Active |
| MC4R | Minimal | Active |
| MC5R | Minimal | Active |
When you need clean MC1R pharmacology, MT-1 gives you a focused probe with fewer off-target signaling variables. When you want broad melanocortin coverage, MT-2’s engagement across MC1R, MC3R, MC4R, and MC5R delivers it, though this trades selectivity for breadth, complicating attribution of any single receptor’s contribution.
What are MT-1 and MT-2
MT-1 and MT-2 are synthetic analogs of α-MSH that differ in structure and melanocortin receptor activity. MT-1, also called Melanotan I or afamelanotide, is a linear tridecapeptide analog of α-MSH. It preserves more of the parent α-MSH pharmacophore, which supports a receptor profile centered on MC1R. MT-2, or Melanotan II, is a cyclic heptapeptide, a lactam-constrained analog. That structural constraint shifts its behavior toward broader melanocortin engagement. Melanotan II research has shown promise in various applications, including tanning and appetite suppression. Recent studies have highlighted its potential benefits in treating conditions like erythropoietic protoporphyria.
Don’t confuse these with the melatonin receptors MT1 and MT2; that’s a separate receptor system entirely. Here, you’re dealing with melanocortin receptor pharmacology. MT-1 leans toward MC1R-dominant activity, while MT-2 acts as a pan-melanocortin agonist across MC1R, MC3R, MC4R, and MC5R. Their structural differences, linear versus cyclic, directly drive these distinct receptor selectivity patterns.
How do the two compounds differ structurally
MT-1 is a linear tridecapeptide, whereas MT-2 is a cyclic heptapeptide with a constrained lactam structure. MT-1, or afamelanotide, is a linear α-MSH analog that preserves much of the parent hormone’s pharmacophore. That structural fidelity keeps MT-1 aligned with α-MSH’s native binding profile, driving its MC1R preference.
MT-2, by contrast, is a cyclic heptapeptide built as a constrained lactam analog. That cyclization locks the peptide into a rigid conformation, and this constrained geometry engages a broader set of receptors rather than favoring one. Klow peptide blend four-compound composition offers a unique approach to peptide design. By leveraging diverse compounds, it aims to enhance biological activity and receptor binding.
What does each target in melanocortin research
Each compound targets different melanocortin receptors. MT-1 concentrates its activity on MC1R, retaining the α-MSH pharmacophore that drives melanocyte signaling and melanogenesis. When you’re studying pigmentation, photoprotection, or MC1R-specific pharmacology, MT-1 gives you a cleaner readout with fewer off-target complications.
MT-2 casts a wider net. Its cyclic structure engages MC1R, MC3R, MC4R, and MC5R, making it a pan-melanocortin agonist rather than a selective probe. It is applied to broader receptor-signaling questions, appetite through MC4R, sexual function, and systemic effects that MC1R alone can’t explain. Importantly, MT-2 shows little meaningful MC2R affinity despite this breadth.
Why does receptor selectivity matter in these studies
Receptor selectivity matters because it determines whether your readouts reflect one receptor system or mixed melanocortin signaling. With MT-1’s MC1R-dominant profile, you isolate melanogenesis pathways in melanocytes, attributing your readouts to one receptor system. That clarity matters when your endpoint is pigmentation or photoprotection, you’re not confounding results with MC3R, MC4R, or MC5R signaling.
MT-2 changes the equation. Its pan-melanocortin activity across MC1R, MC3R, MC4R, and MC5R generates mixed phenotypes, so you can’t cleanly assign appetite, sexual function, or systemic readouts to a single mechanism. You’re capturing broad receptor engagement, not selective pharmacology.
Selectivity determines interpretability. If you want mechanistic precision, MT-1 gives you a cleaner MC1R probe. If you’re mapping broader melanocortin signaling, MT-2’s non-selectivity becomes the feature you’re studying.
How to choose between MT-1 and MT-2 for research
Choose MT-1 for MC1R-focused research and MT-2 for studies requiring broader melanocortin receptor engagement. If you’re probing MC1R pharmacology, melanogenesis, pigmentation signaling, photoprotection, reach for MT-1. Its linear tridecapeptide structure preserves the α-MSH pharmacophore, giving you MC1R-dominant activity and a cleaner readout with fewer off-target signaling variables. GLOW vs KLOW skin blends offer unique formulations tailored to specific skin needs. Identifying which blend suits your requirements can enhance your skincare routine significantly.
If your endpoint spans multiple melanocortin receptors, choose MT-2. Its cyclic heptapeptide constraint drives pan-melanocortin engagement across MC1R, MC3R, MC4R, and MC5R, making it the tool for broader receptor-signaling studies and systemic readouts like appetite and sexual function.
Shop Research Peptides at Holas
Research into melanocortin receptor selectivity and MT-1 vs MT-2 comparisons requires peptides you can trust for verified purity. Holas supplies laboratory-grade research peptides, third-party tested and shipped under sterile handling standards for research use. Browse our shop or contact us to source what you need for your work.
Frequently Asked Questions
Are MT-1 and MT-2 the Same as Melatonin Receptors?
No. In melanocortin research, MT-1 and MT-2 refer to Melanotan I (afamelanotide) and Melanotan II, synthetic α-MSH analogs that target melanocortin receptors. MT-1 acts mainly on MC1R, while MT-2 engages MC1R, MC3R, MC4R, and MC5R. These should not be confused with the melatonin receptors MT1 and MT2, which belong to an entirely different receptor system with distinct signaling and physiological roles.
Does MT-2 Have Any Meaningful MC2R Affinity?
No, MT-2 shows no meaningful MC2R affinity. It behaves as a broad pan-melanocortin agonist across MC1R, MC3R, MC4R, and MC5R, while MC2R remains largely off its target list. That distinction matters when mapping its receptor profile, since MC2R sits apart from the receptors MT-2 engages. For studies focused on MC2R pharmacology, MT-2 does not provide useful coverage despite its otherwise non-selective behavior.
Which Compound Is More Stable for Storage and Handling?
MT-2 typically offers greater handling stability, since its cyclic heptapeptide structure resists degradation better than MT-1’s linear tridecapeptide backbone. The constrained lactam ring limits enzymatic and conformational breakdown, making it a more durable probe. MT-1’s linear α-MSH-like chain is comparatively more susceptible to cleavage. Where storage resilience is a priority, MT-2’s cyclic architecture has the edge, though cold, lyophilized conditions suit both.
Can MT-1 and MT-2 Be Used Together in Studies?
Yes, they pair well in comparative studies, with MT-1 serving as an MC1R-selective probe against MT-2’s pan-melanocortin activity across MC1R, MC3R, MC4R, and MC5R. A side-by-side design helps isolate MC1R-driven melanogenesis from broader receptor signaling, separating pigment-focused readouts from MC3R and MC4R-mediated pathways and mapping which phenotypes trace to which receptors in the model system.
Are There Recommended Assay Methods for Measuring Receptor Selectivity?
Receptor selectivity is typically measured with functional cAMP accumulation assays, since melanocortin receptors signal through Gs. Dose-response curves at each receptor, MC1R, MC3R, MC4R, and MC5R, generate EC50 values for comparing potency ratios. These pair well with radioligand or fluorescent binding assays for affinity (Ki) data. Testing MT-1 and MT-2 side by side across all four receptors quantifies MC1R dominance versus pan-melanocortin activation directly.
